The Charnolosome as a Novel Nanothereranostic Biomarker

Overcoming Future Challenges in Medicine

Häftad, Engelska, 2024

4 479 kr

Beställningsvara. Skickas inom 7-10 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author’s original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases.

The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions.

Shares the latest knowledge on the charnolosome and charnolosome-derived nano-vesicles and their significance at a cellular and molecular level
Considers the charnolosome in relation to a range of conditions, including neurodegenerative, metabolic, and multi-drug resistant systemic diseases
Presents future perspectives of the charnolosome in personalized nanotheranostics

Produktinformation

Utgivningsdatum2024-09-27
Mått216 x 276 x undefined mm
Vikt2 530 g
FormatHäftad
SpråkEngelska
Antal sidor968
FörlagElsevier Science
ISBN9780443217524

Tillhör följande kategorier

Biologi inom Naturvetenskap och teknik

Section I: General Topics1. Transcriptional regulation of Charnolosome through gene/base-editing2. Charnolosome destabilization induces inflammasome activation3. Charnolosome in Charnoly Body molecular pathogenesis of gene-manipulated cells and animals4. Charnolosome and inflammasome in chronic MDR diseases5. Charnolosome stabilization inhibits inflammasome to confer personalized nanotheranostic benefit in chronic MDR diseases6. Endogenous, natural, and synthetic antioxidants stabilize charnolosome and its exocytosis to confer theranostic benefit by inflammasome inhibition7. Charnolosome stability index (stabilized Charnolosome vs activated inflammasome) determines normal cellular function to remain healthy8. Charnolosome stability index regulates Charnoly Body molecular pathogenesis9. Nanotheranostic significance of antioxidants in Charnolosome detoxification10. Theranostic significance of Charnolosome in personalized nanomedicine11. Environmental toxins and transcriptional regulation of Charnolosome12. Antioxidants-mediated Charnolosome transcriptional regulation in health and disease13. Mitochondrial bioenergetics, Charnosome, and theranostic potential of antioxidants14. Cellular, molecular, and genetic significance of metallothioneins as Charnolosome modulators15. Pharmacogenomics of metallothioneins and other endogenous, natural, and synthetic antioxidants as CS Regulators in health and disease16. Environmental pollution and metal ion speciation of metallothioneins17. Metallothioneins as potential charnolopharmacotherapeutics18. Antioxidants as Charnolosome stabilizers, charnolophagy enhancers, and intracellular detoxifiers.19. Charnolosomaging triggers inflammaging to induce charnoptosis, pyroptosis, and ferroptosis in chronic MDR diseases in aging20. Charnolosome as a theranostic biomarker in cell therapy and nanomedicineSection II: Special TopicsPart 1: Malnutrition, Stress, Inflammation, Microbial Infections, and Ionizing Radiation Injuries21. Charnolosome in malnutrition22. Charnolosome in stress23. Charnolosome in inflammation24. Charnolosome in microbial infections25. Charnolosome in ionizing radiation injuriesPart 2: Congenital & Metabolic Diseases26. Charnolosome in congenital diseases27. Charnolosome in metabolic diseases28. Charnolosome in hyperlipidemia29. Charnolosome in obesity30. Charnolosome in diabetes31. Charnolosome in hepatic diseases32. Charnolosome in GIT diseasesPart 3: Multidrug-Resistant Systemic Diseases33. Charnolosome in skin diseases34. Charnolosome in musculo-skeletal diseases35. Charnolosome in pulmonary diseases36. Charnolosome in cardiovascular diseases37. Charnolosome in renal diseases38. Charnolosome in reproductive diseasesPart 4: Neuropsychiatric & Neurodegenerative Diseases39. Charnolosome in polysubstance abuse40. Charnolosome in neuropsychiatric diseases41. Charnolosome in neurodegenerative diseases42. Charnolosome in Neurodegenerative α-Synucleinopathies43. Charnolosome in Parkinson’s Disease44. Charnolosome in Alzheimer’s Disease and other taupathies45. Charnolosome in stroke & traumatic brain injury46. Attenuation of Charnolosome-Mediated Neurodegenerative α-Synucleinopathies by antioxidants47. Charnolosome as a novel nanotheranostic biomarker of agingPart 5: Inflammatory Diseases, Autoimmune Diseases, Cancer, & Infectious Diseases48. Charnolosome in Inflammatory Diseases49. Charnolosome in autoimmune diseases50. Charnolosome in cancer51. Charnolosome in infectious diseasesSection III: Future Prospects52. Charnolosomics in nanomedicine (Recent Update)53. Charnolosome-based disease-specific nanopharmacotherapeutics54. Physiological, Biochemical, Pharmacological, and Genetic Manipulation of Charnolosome in Personalized Nanotheranostics of Chronic MDR Diseases55. Transcriptional and translational regulation of Charnolosome in multi-drug resistant malignancies and other chronic diseases56. Future prospectus of Charnolosome in evidence-based personalized nanotheranostics